Barclays’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.62M | Buy |
121,130
+61,270
| +102% | +$818K | ﹤0.01% | 2373 |
|
|
2025
Q1 | $611K | Sell |
59,860
-47,682
| -44% | -$487K | ﹤0.01% | 2721 |
|
|
2024
Q4 | $1.7M | Buy |
107,542
+47,528
| +79% | +$753K | ﹤0.01% | 2314 |
|
|
2024
Q3 | $3.48M | Buy |
60,014
+35,022
| +140% | +$2.03M | ﹤0.01% | 1780 |
|
|
2024
Q2 | $1.14M | Sell |
24,992
-44,664
| -64% | -$2.04M | ﹤0.01% | 2051 |
|
|
2024
Q1 | $4.61M | Sell |
69,656
-190,104
| -73% | -$12.6M | ﹤0.01% | 1420 |
|
|
2023
Q4 | $10.3M | Buy |
259,760
+210,249
| +425% | +$8.36M | ﹤0.01% | 1042 |
|
|
2023
Q3 | $1.58M | Buy |
49,511
+11,118
| +29% | +$354K | ﹤0.01% | 1800 |
|
|
2023
Q2 | $1.54M | Buy |
38,393
+9,047
| +31% | +$363K | ﹤0.01% | 1904 |
|
|
2023
Q1 | $1.25M | Sell |
29,346
-8,589
| -23% | -$367K | ﹤0.01% | 1978 |
|
|
2022
Q4 | $1.82M | Sell |
37,935
-59,640
| -61% | -$2.86M | ﹤0.01% | 1693 |
|
|
2022
Q3 | $3.67M | Buy |
97,575
+63,658
| +188% | +$2.39M | ﹤0.01% | 1278 |
|
|
2022
Q2 | $936K | Buy |
33,917
+21,197
| +167% | +$585K | ﹤0.01% | 2138 |
|
|
2022
Q1 | $691K | Buy |
+12,720
| New | +$691K | ﹤0.01% | 2574 |
|